NCT06971549

Brief Summary

This study will investigate the cortical hemodynamic response variability of an accelerated form of TBS stimulation over left dorsolateral prefrontal cortex (DLPFC) using a concurrent TBS/fNIRS setup. The accelerating TMS protocol that will be used in this study is similar to the Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT), i.e., fifty iTBS sessions (1,800 pulses per session, 50-minute intersession interval) will be delivered as 10 daily sessions over 5 consecutive days at 90% resting motor threshold. The investigators will recruit a depressed patient and conduct a concurrent iTBS/fNIRS protocol for each iTBS session. Moreover, the depression symptoms of the patient will be assessed before and after treatment.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
1

participants targeted

Target at below P25 for not_applicable depression

Timeline
Completed

Started Mar 2025

Shorter than P25 for not_applicable depression

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 19, 2025

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

April 27, 2025

Completed
17 days until next milestone

First Posted

Study publicly available on registry

May 14, 2025

Completed
17 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 31, 2025

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

June 30, 2025

Completed
Last Updated

May 14, 2025

Status Verified

May 1, 2025

Enrollment Period

2 months

First QC Date

April 27, 2025

Last Update Submit

May 6, 2025

Conditions

Keywords

Theta-Burst stimulation (iTBS)Functional near-infrared spectroscopy (fNIRS)Concurrent TMS/fNIRSPrefrontal hemodynamic response

Outcome Measures

Primary Outcomes (2)

  • Oxygenated and deoxygenated hemoglobin (HbO and HbR) change compared to baseline

    iTBS-induced HbO and HbR change in the DLPFC before, during and after stimulation

    Before, during and immediately after the intervention

  • Hamilton Depression Rating Scale (HAM-D)

    The Hamilton Depression Rating Scale, 17 item (HAM-D-17) is a simple, clinician-administered tool used to assess symptoms of depression experienced by a patient in the past week. The values of HAM-D-17 range from 0 to 52, and higher socres mean more severe symptoms.

    through study completion, an average of 5 days

Secondary Outcomes (3)

  • Montgomery-Asberg depression rating scale (MADRS)

    through study completion, an average of 5 days

  • Patient Health Questionnaire-9 (PHQ-9)

    daily for 5 days

  • Verbal Analogue Scale (VAS) fatigue and pain level

    immediately after the intervention

Study Arms (1)

Accelerating TMS teatment

EXPERIMENTAL

One depressed patient will be included in this study, which lasts for 5 consecutive days. During these 5 days, the participant will receive accelerated TMS treatment based on SAINT protocol, simultaneously monitored by concurrent TMS/fNIRS.

Other: Accelerated iTBS

Interventions

Fifty iTBS sessions (1,800 pulses per session, 50-minute intersession interval) will be delivered as 10 daily sessions over 5 consecutive days at 90% resting motor threshold.

Accelerating TMS teatment

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • aged 18 to 65;
  • a clinical diagnosis of current nonpsychotic major depressive disorder by an experienced psychiatrist according to DSM-IV;
  • no or stable (≥2 weeks) psychopharmacological medication;
  • have not responded to at least one antidepressant medication;
  • have not received any TMS treatment;
  • and have a 17-item HAMD score ≥ 20.

You may not qualify if:

  • severe internal diseases;
  • neurological disorders or a history of severe head injuries;
  • having suicidal ideation;
  • pregnancy;
  • antiepileptics and benzodiazepines corresponding to a dose of \>1 mg lorazepam/d.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

The Hong Kong Polytechnic University

Hong Kong, Hong Kong

RECRUITING

MeSH Terms

Conditions

Depression

Condition Hierarchy (Ancestors)

Behavioral SymptomsBehavior

Study Officials

  • Georg Kranz, PhD

    The Hong Kong Polytechnic University

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Georg Kranz, PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

April 27, 2025

First Posted

May 14, 2025

Study Start

March 19, 2025

Primary Completion

May 31, 2025

Study Completion

June 30, 2025

Last Updated

May 14, 2025

Record last verified: 2025-05

Data Sharing

IPD Sharing
Will not share

Locations